Category: 10581-12-1

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10581-12-1,Tetramethylammonium acetate,as a common compound, the synthetic route is as follows.

A solution of H3F3ST (300mg, 0.39mmol) dissolved in 6mL of anhydrous dimethylacetamide (DMA) was treated with solid NaH (28mg, 1.2mmol). The mixture was stirred until gas evolution ceased. Fe(OAc)2 (68mg, 0.39mmol) and NMe4OAc (52mg, 0.39mmol), were added to the cloudy white reaction, and the solution was stirred. After 3h, 5mL of Et2O was added to the yellow solution to aid the precipitation of NaOAc. The reaction mixture was filtered through a medium porosity glass-fritted funnel to remove the insoluble species and the filtrate was dried under vacuum. The resulting pale yellow solid was redissolved in 5mL of acetonitrile (MeCN), stirred for 20min, and filtered using a fine porosity glass-fritted funnel. The filtrate was concentrated under vacuum to ca. 1mL and treated with Et2O (10mL) then pentane (40mL) to precipitate a pale yellow solid. The pale yellow solid was collected on a medium porosity glass-fritted funnel and dried under vacuum to give 182mg (91%) of product. FTIR (KBr disc, cm-1, selected bands): 3413, 3046, 2964, 2902, 2861, 1608, 1490, 1403, 1326, 1263, 1134, 1062, 976, 821, 710, 622, 605. MS (ES-, m/z): Exact mass calcd for C27H24N4O6S3F9Fe: 823.0, Found: 823.1.

10581-12-1, As the paragraph descriping shows that 10581-12-1 is playing an increasingly important role.

Reference£º
Article; Lau, Nathanael; Ziller, Joseph W.; Borovik; Polyhedron; vol. 85; (2015); p. 777 – 782;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10581-12-1,Tetramethylammonium acetate,as a common compound, the synthetic route is as follows.

General procedure: The appropriate ligand (H3LR)(0.18 mmol, R=OMe, Me H, Cl, Br), was deprotonated with 3.1 molar equiv. KH in3mL of DMA in a 25-50-mL round bottom flask. After H2 evolution ceased (?5-10 min), an excess 1.2 eq of Mn(OAc)2 was added along with 1mL of DMA andstirred for 30 min. Then 2.1 equivalents of [Me4N][OAc] were added along with 1mL ofDMA and the reaction was stirred at room temperature overnight. The mixture was filteredthrough a glass fritted funnel to remove insoluble material. The filtrate was layeredunder Et2O and allowed to stand for recrystallization. In most cases a whitecrystalline solid was obtained and isolated by filtration. In some cases, an oily residuewas obtained that through trituration with Et2O and scraping yields a white solid. Ineither case, the solids from DMA/Et2O was then redissolved in acetonitrile and filteredto remove insoluble material. Recrystallization was accomplished by slow vapor diffusionof Et2O into acetonitrile. The solids obtained were washed with diethyl ether anddried under vacuum. See below for characterization data for the remainingMn(II) complexes.

10581-12-1, The synthetic route of 10581-12-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Cannella, Anthony F.; Surendhran, Roshaan; MacMillan, Samantha N.; Gupta, Rupal; Lacy, David C.; Journal of Coordination Chemistry; vol. 72; 8; (2019); p. 1287 – 1297;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10581-12-1, Tetramethylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 2 In a round flask, 2 mL of methyl cyanide (acetonitrile) as an organic solvent was introduced, 0.145 g (1 mmol) of 5-chloromethylfurfural (CMF, compound I) was dissolved in the organic solvent, 0.133 g (1 mmol) of tetramethylammonium acetate was added to the solution, and then the mixed solution was reacted at normal pressure and room temperature for 5 minutes. After the reaction, the reaction product was extracted by the addition of a small amount of water (5 mL) and ethyl acetate (added twice by 20 mL) to obtain an organic layer. The obtained organic layer was concentrated under reduced pressure to obtain light yellow liquid 5-acetoxymethylfurfural (AcHMF, compound II). The yield thereof is 95%. It was ascertained by 1H-NMR that the light yellow liquid is a target material. Analysis data is as follows. AcHMF: 1H NMR (400 MHz, CDCl3) 9.65 (s, 1H), 7.25 (d, J=3.6, 1H), 6.62 (d, J=3.6, 1H), 5.13 (s, 2H), 2.12 (s, 3H)

10581-12-1, 10581-12-1 Tetramethylammonium acetate 82741, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Kim, Baek Jin; Cho, Jin Ku; Kim, Sangyong; Lee, Do Hoon; Kim, Young Gyu; Kang, Eun-Sil; Hong, Yeon-Woo; Chae, Da Won; US2015/51413; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10581-12-1, Tetramethylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

10581-12-1, General procedure: The appropriate ligand (H3LR)(0.18 mmol, R=OMe, Me H, Cl, Br), was deprotonated with 3.1 molar equiv. KH in3mL of DMA in a 25-50-mL round bottom flask. After H2 evolution ceased (?5-10 min), an excess 1.2 eq of Mn(OAc)2 was added along with 1mL of DMA andstirred for 30 min. Then 2.1 equivalents of [Me4N][OAc] were added along with 1mL ofDMA and the reaction was stirred at room temperature overnight. The mixture was filteredthrough a glass fritted funnel to remove insoluble material. The filtrate was layeredunder Et2O and allowed to stand for recrystallization. In most cases a whitecrystalline solid was obtained and isolated by filtration. In some cases, an oily residuewas obtained that through trituration with Et2O and scraping yields a white solid. Ineither case, the solids from DMA/Et2O was then redissolved in acetonitrile and filteredto remove insoluble material. Recrystallization was accomplished by slow vapor diffusionof Et2O into acetonitrile. The solids obtained were washed with diethyl ether anddried under vacuum. See below for characterization data for the remainingMn(II) complexes.

10581-12-1 Tetramethylammonium acetate 82741, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Cannella, Anthony F.; Surendhran, Roshaan; MacMillan, Samantha N.; Gupta, Rupal; Lacy, David C.; Journal of Coordination Chemistry; vol. 72; 8; (2019); p. 1287 – 1297;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10581-12-1, Tetramethylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

CORM-349 [Me4N][(OC)3Mn(mu-OCOCH3)3Mn(CO)3]; 150 mg (0.436 mmol) of Mn(CO)5(SO3CF3) and 116 mg (0.872 mmol) of [Me4N][acetate] were stirred in 8 ml of dry THF and 2 ml of methanol, under argon at 50-55 C. for 3 hrs. During this time the colour of the solution went a little darker yellow/orange.Following this, the solvent was removed on rotary evaporator to give a yellow/orange semi-solid residue. This was crystallised from DCM/Ether at -18 C. to give a yellow crystalline product (123 mg, 0.232 mmol). Yield was 100%.Based on the preliminary IR data, the product was initially identified as [Me4N][(Mn(CO)4(OAc)2]. However, additional analysis, particularly X ray crystal structure analysis, has revealed that the product has the title structure. Furthermore, mass spectral data also supports a product having more than one Mn atom.Mr=529.21.1H NMR (CD2Cl2): delta(ppm) 2.29 (s, acetate CH3 6H), 3.33 (s, NMe4 12H)13C NMR (CD2Cl2): delta(ppm) 23.55 (acetate CH3), 56.34 (NMe4), 176.15 (CO), 224.20 (CO)17O NMR (CD2Cl2): delta(ppm) 388.6 (CO)IR (CH2Cl2) nu(cm-1): 2027 (s), 1930 (vs)Mass Spec (ES-) (m/z): 455 ([Mn2(CO)6(OAc)3]-); 315 ([Mn2(CO)(OAc)3]- or [Mn2(CO)4(OAc)(OH)2]-); 257 ([Mn(CO)3(OAc)2]-)Elemental: C16H21Mn2NO12 found (calc) C: 36.80 (36.31), H: 4.90 (4.00), N: 3.60 (2.65)The dimeric structure of the anion has been established by x-ray crystallography.

10581-12-1, As the paragraph descriping shows that 10581-12-1 is playing an increasingly important role.

Reference£º
Patent; Motterlini, Roberto Angelo; Mann, Brian Ernest; Scapens, David Alistair; US2010/105770; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10581-12-1,Tetramethylammonium acetate,as a common compound, the synthetic route is as follows.

General procedure: A solution of H3F3ST (300mg, 0.39mmol) dissolved in 6mL of anhydrous dimethylacetamide (DMA) was treated with solid NaH (28mg, 1.2mmol). The mixture was stirred until gas evolution ceased. Fe(OAc)2 (68mg, 0.39mmol) and NMe4OAc (52mg, 0.39mmol), were added to the cloudy white reaction, and the solution was stirred. After 3h, 5mL of Et2O was added to the yellow solution to aid the precipitation of NaOAc. The reaction mixture was filtered through a medium porosity glass-fritted funnel to remove the insoluble species and the filtrate was dried under vacuum. The resulting pale yellow solid was redissolved in 5mL of acetonitrile (MeCN), stirred for 20min, and filtered using a fine porosity glass-fritted funnel. The filtrate was concentrated under vacuum to ca. 1mL and treated with Et2O (10mL) then pentane (40mL) to precipitate a pale yellow solid. The pale yellow solid was collected on a medium porosity glass-fritted funnel and dried under vacuum to give 182mg (91%) of product., 10581-12-1

10581-12-1 Tetramethylammonium acetate 82741, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Lau, Nathanael; Ziller, Joseph W.; Borovik; Polyhedron; vol. 85; (2015); p. 777 – 782;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10581-12-1,Tetramethylammonium acetate,as a common compound, the synthetic route is as follows.

To a solution of compound 3 (20g, 42.8mmol, 1.0eq) in Toluene (200mL) was added tetra methyl ammonium acetate (14.3g, 54.8mmol, 1.28eq) at rt. The mixture was heated to reflux for 16h. TLC analysis indicated formation of a polar spot. Then the reaction mass was extracted with EtOAc (2 X 200m L) and washed with water (2 X 100ml_) and brine (2 X 100ml_). The organic layer was dried under reduced pressure. The residue (40 g) was taken up with 80ml_ of 2-prpoanol. The mixture was stirred at 0C for 30 mins and the resulting Crystalline product was collected under dried under vaccum to give compound 4 (12 g, 68%) as a pale yellow color Solid. LCMS: 79.34% with m/z 356.24 (M+H):

10581-12-1, As the paragraph descriping shows that 10581-12-1 is playing an increasingly important role.

Reference£º
Patent; ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR); AL-AWAR, Rima; ISAAC, Methvin; CHAU, Anh My; MAMAI, Ahmed; WATSON, Iain; PODA, Gennady; SUBRAMANIAN, Pandiaraju; WILSON, Brian; UEHLING, David; PRAKESCH, Michael; JOSEPH, Babu; MORIN, Justin-Alexander; (441 pag.)WO2019/153080; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI